About
Small Molecules for Musculoskeletal Diseases
Areas of Focus
Categories
Small Molecule PharmaceuticalMountain West
Team (13)
Alan Russell, Ph.D.
Director and Co-Founder
Edgewise Therapeutics
founder
Arlene Morris
Director
Edgewise Therapeutics
team_member
Badreddin Edris, Ph.D.
Director and Co-Founder
Edgewise Therapeutics
founder
Behrad Derakhshan, Ph.D.
Chief Operating Officer
Edgewise Therapeutics
executive
Joanne M. Donovan, M.D., Ph.D.
Chief Medical Officer
Edgewise Therapeutics
executive
John Moore
General Counsel
Edgewise Therapeutics
executive
Clinical Trials (16)
View allTotal Trials
16
As Lead Sponsor
14
As Collaborator
2
Total Enrollment
1,199
By Phase
PHASE1: 9PHASE2: 5
By Status
COMPLETED: 8ACTIVE_NOT_RECRUITING: 4RECRUITING: 3ENROLLING_BY_INVITATION: 1
Clinical Trials Pipeline16 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT07177066Lead Sponsor
A Study of EDG-15400 in Healthy Adults
PHASE1Recruiting
108 participants
Started: Aug 20, 2025 · Completed: May 31, 2026
NCT07034768Lead Sponsor
A Study to Evaluate EDG-7500 in People With Renal Impairment
PHASE1Recruiting
48 participants
Started: Jul 22, 2025 · Completed: Dec 31, 2025
NCT06916897Lead Sponsor
A Study to Evaluate Effect of Verapamil and Food of Sevasemten in Healthy Volunteers
PHASE1Completed
42 participants
Started: Jan 8, 2025 · Completed: Feb 22, 2025
NCT06738836Lead Sponsor
A Study to Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C]-EDG-7500
PHASE1Completed
8 participants
Started: Dec 3, 2024 · Completed: Jan 17, 2025
NCT06347159Lead Sponsor
A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)
PHASE2Recruiting
75 participants
Started: Apr 11, 2024 · Completed: Mar 31, 2026
Locations (1)
Headquarters
Boulder, CO, United States
Map
Loading map...